SomaLogic Signs Collaborative Agreement With Novo Nordisk To Support Drug Development Efforts

SomaLogic, Inc., a global leader in proteomics technology, announced today that it is adding to its list of collaborative agreements with global healthcare innovator, Novo Nordisk. As part of the agreement, Novo Nordisk will expand the use of the SomaScan technology platform for their drug development research in non-alcoholic steatohepatitis (NASH), cardiovascular disease and diabetes.

Novo Nordisk will also provide proteins to SomaLogic that will help expand their proteomics platform to 10,000 proteins, more than six times the protein menu offerings of the current competitors. Novo Nordisk used SomaLogic’s SomaSignal tests in previous drug development efforts and will continue to use the tests as part of this agreement.

“SomaSignal tests offer deep insights into human health and give our customers an important tool in their work in drug research and development,” said SomaLogic’s Executive Vice President, Life Sciences Markets Tracy Hervey. “This collaborative agreement will support Novo Nordisk in their drug discovery work and in the clinical development of potentially life saving therapies.”

Each SomaSignal test is built on SomaLogic’s proprietary SomaScan Platform, which offers what is believed to be the broadest view available of the proteome. The platform is capable of potentially identifying new biomarkers, novel drug targets and improving the assessment and management of therapeutic responses. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 450,000 samples to date.